Literature DB >> 22565900

Orbicularis oculi myocutaneous island flap for upper eyelid reconstruction.

Sang Wha Kim1, Hyun Ho Han, Sung-No Jung.   

Abstract

The cosmetic and functional outcomes of a reconstruction of an upper eyelid defect due to trauma or neoplasm are very important. This article reports the technique of an orbicularis oculi myocutaneous island flap for covering small- to moderate-sized defects of the upper eyelid. Between March 2008 and March 2010, 5 patients underwent surgery for an upper eyelid reconstruction. After tumor excision and debridement, the eyelid margin was closed directly before the reconstruction. The flap was designed just beside the defect considering the amount of tissue remaining for the reconstruction. The flap was elevated by splitting the muscle by the direction of its fibers without damaging the pedicle. The elevated flap was then transposed to the defect without tension.The orbicularis oculi myocutaneous flap is a single-stage reconstruction with reliable vascularity. It can be used to cover a defect without compromising the primary closure of the donor site and can be customized to reconstruct the defect with minimal tissue. Therefore, an orbicularis oculi myocutaneous island flap can be an alternative for a single-stage reconstruction of small- to moderate-sized defects of the upper eyelid.

Entities:  

Mesh:

Year:  2012        PMID: 22565900     DOI: 10.1097/SCS.0b013e31824dbdb6

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  2 in total

1.  Medial and lateral canthal reconstruction with an orbicularis oculi myocutaneous island flap.

Authors:  Jihyeon Han; Sung Tack Kwon; Suk Wha Kim; Eui Cheol Jeong
Journal:  Arch Plast Surg       Date:  2015-01-14

2.  Extensive full-thickness eyelid reconstruction with rotation flaps through "subcutaneous tunnel" and palatal mucosal grafts.

Authors:  Jian-Xia Cheng; Lan Zuo; Xin-Yu Huang; Ji-Zhe Cui; Shuai Wu; Yuan-Yuan Du
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.